A total of 61 patients were reported to have rare cancer types including brain cancer, (12 patients; 1 with PV in the MSH2 gene), thyroid cancer, (9 patients; 1 with PV in the BRCA2 gene), melanoma (25 patients; 4 patients with PV in PALB2, BRCA2 or the CHEK2 gene), sarcoma (12 patients; 2 with a PV in MLH1 and CHEK2 gene, respectively) and hematological cancer (three patients). This evidence concerns the gene MSH2 and cancer.